{
    "nctId": "NCT00263588",
    "briefTitle": "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer",
    "officialTitle": "A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 242,
    "primaryOutcomeMeasure": "The Number of Participants With Central Nervous System (CNS) Best Overall Response",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Signed Informed Consent\n* ErbB2(HER2)overexpressing breast cancer.\n* Brain lesion(s) which are progressing.\n* Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS).\n* Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy.\n* Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram.\n* Able to swallow an oral medication.\n* Adequate kidney and liver function.\n* Adequate bone marrow function.\n\nExclusion criteria:\n\n* Pregnant or lactating females.\n* Conditions that would effect the absorption of an oral drug.\n* History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.\n* Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.\n* Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}